Adamas Announces Positive Top-Line Phase 3 Results of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson’s Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Adamas Pharma (ADMS) Sees Red-to-Green Move
December 24, 2015 11:28 AM ESTAfter trading down as much as 8% earlier, yesterday's big mover Adamas Pharma (NASDAQ: ADMS) is back in positive territory.
... MoreAdamas Pharmaceuticals (ADMS) PT Raised to $37 at Credit Suisse
December 24, 2015 7:37 AM ESTCredit Suisse analyst V. Divan reiterated an Outperform rating and raised its price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to $37.00 (from $35.00) after raising the probability of success for ADS-5102 to 90% (from 80%) on the back of encouraging topline phase 3 data for their lead internal asset... More
Adamas Pharma (ADMS) Ramps Into the Close
December 23, 2015 3:38 PM ESTAdamas Pharma (NASDAQ: ADMS) ramps into the close. Shares are up 73.6% and near the highs after earlier announcing statistically significant ADS-5102 Phase 3 EASE LID data.
... MoreAdamas Pharmaceuticals (ADMS) PT Raised to $38 at Needham & Company
December 23, 2015 2:18 PM ESTNeedham & Company analyst Serge Belanger reiterated a Buy rating and raised his price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to $38.00 (from $33.00) after the company reported positive top-line results from its first ph 3 study evaluating ADS-5102 in the treatment of levodopa-induced dyskinesia (LID) in Parkinson's... More
Piper Jaffray Remains Bullish on Adamas Pharmaceuticals (ADMS)
December 23, 2015 9:12 AM ESTWhile no note was issued, Piper Jaffray's David Amsellem remains positive on Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) which is up over 30% premarket after its phase 3 trial for ADS-5102 (amantadine HCI) ER in Parkinson's (LID) meeting primary endpoint.
